{
    "clinical_study": {
        "@rank": "121100", 
        "acronym": "LL RCT", 
        "arm_group": [
            {
                "arm_group_label": "Lutonix DCB", 
                "arm_group_type": "Experimental", 
                "description": "Lutonix Paclitaxel Drug Coated Balloon"
            }, 
            {
                "arm_group_label": "PTA Catheter", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard Uncoated Balloon Angioplasty Catheter"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of long\n      (\u2265 14 cm) lesions in the femoropopliteal artery (SFA)."
        }, 
        "brief_title": "Lutonix\u00ae DCB Versus Standard Balloon Angioplasty for Treatment of Long Lesions in Femoropopliteal Arteries", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Femoral Artery Occlusion", 
            "Femoral Arterial Stenosis"
        ], 
        "condition_browse": {
            "mesh_term": "Arterial Occlusive Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Clinical Criteria\n\n          1. \u2265 18 years of age;\n\n          2. Rutherford Clinical Category 2-4;\n\n          3. Subject is legally competent and voluntarily agrees to participation and the study's\n             provisions;\n\n          4. \u2265 70% stenosis of a native femoropopliteal artery;\n\n          5. TASC II Class C or D Lesions with intended target lesion treatment segment(s)\n             cumulatively \u226514 cm in length;\n\n          6. de novo lesion(s) or non-stented restenotic lesion(s) > 90 days from prior\n             angioplasty procedure;\n\n          7. Target vessel diameter between \u2265 4 and \u2264 7 mm;\n\n          8. Successful wire crossing of lesion and predilatation;\n\n          9. No other prior vascular interventions (including contralateral limb) within 2 weeks\n             before and/or planned 30 days after the protocol treatment.\n\n        Exclusion Criteria:\n\n          1. Patient is contraindicated to use Lutonix Drug Coated Balloon per the current\n             Instructions For Use (IFU);\n\n          2. Life expectancy of < 1year;\n\n          3. Patient is currently participating in an investigational drug or other device study\n             or previously enrolled in this study;\n\n          4. History of stroke within 3 months;\n\n          5. History of myocardial infarction, thrombolysis or angina within 2 weeks of\n             enrollment;\n\n          6. Prior vascular surgery of index limb with exception of remote common femoral patch\n             angioplasty;\n\n          7. Target lesion involves a previously placed stent;\n\n          8. Inability to take required study medications or allergy to contrast that cannot be\n             adequately managed with pre- and post-procedure medication;\n\n          9. Significant inflow disease;\n\n         10. Known inadequate distal outflow or planned future treatment of vascular disease;\n\n         11. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in\n             target vessel;\n\n         12. Use of adjunctive treatment modalities (e.g. laser, atherectomy or cryoplasty)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013271", 
            "org_study_id": "CL0017-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lutonix DCB", 
                "intervention_name": "Lutonix Paclitaxel Drug Coated Balloon", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "PTA Catheter", 
                "description": "PTA Catheter", 
                "intervention_name": "Standard Uncoated Balloon Angioplasty Catheter", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "University Clinical Center Heidelberg"
                }, 
                "investigator": {
                    "last_name": "Britta Vogel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Regensburg", 
                        "country": "Germany", 
                        "zip": "93049"
                    }, 
                    "name": "Krankenhaus Barmherzige Br\u00fcder Regensburg"
                }, 
                "investigator": {
                    "last_name": "Niels Zorger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sonneberg", 
                        "country": "Germany", 
                        "zip": "96515"
                    }, 
                    "name": "Medinos Kliniken Sonneberg"
                }, 
                "investigator": {
                    "last_name": "Marcus Thieme, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix\u00ae Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Long Lesions in Femoropopliteal Arteries", 
        "overall_contact": {
            "email": "NHP-Lutonix-LLRCT@crbard.com", 
            "last_name": "Lisa Erickson"
        }, 
        "overall_official": [
            {
                "affiliation": "Cantonal Hospital Lucerne", 
                "last_name": "Martin Banyai, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University Hospital, Bordeaux", 
                "last_name": "Prof. Eric Ducasse, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Freedom from death, target limb amputation, and Target Lesion Revascularization (TLR)", 
                "safety_issue": "Yes", 
                "time_frame": "30 Days"
            }, 
            {
                "measure": "Efficacy: Primary Patency", 
                "safety_issue": "No", 
                "time_frame": "12 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following endpoints will be assessed at 1, 6, 12, 24 and 36 months:\nAll-cause death\nAmputation (above the ankle)-Free Survival (AFS)\nTarget Vessel Revascularization (TVR)\nReintervention for treatment of thrombosis of the target vessel or embolization to its distal vasculature\nMajor vascular complications\nReadmission for cardiovascular events", 
                "measure": "Safety: Composite of freedom from all-cause perioperative (\u2264 30 day) death and freedom from the following: target limb amputation, target limb re-intervention, and target-limb-related death.", 
                "safety_issue": "Yes", 
                "time_frame": "1, 6, 12, 24, 36 months"
            }, 
            {
                "description": "The following endpoints will be assessed at 6, 12 and 24 Months:\nPrimary and Secondary Patency\nTarget Lesion Revascularization (TLR)\nClinically-driven\nTotal (clinical and DUS/angiography-driven)\nChange of Rutherford classification from baseline\nChange of resting Ankle Brachial Index (ABI) from baseline\nChange in Walking Impairment Questionnaire from baseline\nChange in quality of life from baseline, as measured by EQ-5D", 
                "measure": "Efficacy: Acute Device, Technical and Procedural success", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 24 months"
            }
        ], 
        "source": "C. R. Bard", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "C. R. Bard", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}